William Y. Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William Y. Shi has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Ash A. Alizadeh
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
7 shared publications - Joseph C. Liao
Department of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA
7 shared publications - Maximilian Diehn
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, USA
7 shared publications - Aadel A. Chaudhuri
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
6 shared publications - Barzin Y. Nabet
Genentech, South San Francisco, USA
6 shared publications - Chih Long Liu
Stanford Cancer Institute, Stanford University, Stanford, USA
6 shared publications
Latest Publications
- Top Cited Papers
Field-effect-informed urine liquid biopsy for bladder cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- Open Access
- 12 July 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 177
Contents
- 12 July 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 177
Open AccessContents
- 19 October 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (3) , 765-766
The Call to Perfection: A High Bar for Sutureless and Rapid Deployment Aortic Valves
- 19 October 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (3) , 765-766
The Call to Perfection: A High Bar for Sutureless and Rapid Deployment Aortic Valves
- Open Access
- 30 June 2021
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 10 (10) , 1140-1147
Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomes
Aims: This study aims to evaluate if pre-hospital heparin administration by paramedics is safe and improves clinical outcomes. Methods and results: Using the multicentre Victorian Cardiac Outcomes Registry, linked with state-wide ambulance records, we identified consecutive patients undergoing primary percutaneous coronary intervention for STEMI between January 2014 and December 2018. Information on thrombolysis in myocardial infarction (TIMI) flow at angiography was available in a subset of cases. Patients receiving pre-hospital heparin were compared to those who did not receive heparin. Findings at coronary angiography and 30-day clinical outcomes were compared between groups. Propensity-score matching was performed for risk adjustment. We identified a total of 4720 patients. Of these, 1967 patients had TIMI flow data available. Propensity-score matching in the entire cohort yielded 1373 matched pairs. In the matched cohort, there was no observed difference in 30-day mortality (no-heparin 3.5% vs. heparin 3.0%, P = 0.25), MACCE (no-heparin 7% vs. heparin 6.2%, P = 0.44), and major bleeding (no-heparin 1.9% vs. heparin 1.4%, P = 0.64) between groups. Propensity-score analysis amongst those with TIMI data produced 552 matched pairs. The proportion of cases with TIMI 0 or 1 flow in the infarct-related artery (IRA) was lower among those receiving pre-hospital heparin (66% vs. 76%, P < 0.001) compared to those who did not. Conclusion : In this multicentre, propensity-score matched study, the use of pre-hospital heparin by paramedics was safe and is associated with fewer occluded IRAs in patients presenting with STEMI.
- 30 June 2021
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 10 (10) , 1140-1147
Open AccessPre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomes
Aims: This study aims to evaluate if pre-hospital heparin administration by paramedics is safe and improves clinical outcomes. Methods and results: Using the multicentre Victorian Cardiac Outcomes Registry, linked with state-wide ambulance records, we identified consecutive patients undergoing primary percutaneous coronary intervention for STEMI between January 2014 and December 2018. Information on thrombolysis in myocardial infarction (TIMI) flow at angiography was available in a subset of cases. Patients receiving pre-hospital heparin were compared to those who did not receive heparin. Findings at coronary angiography and 30-day clinical outcomes were compared between groups. Propensity-score matching was performed for risk adjustment. We identified a total of 4720 patients. Of these, 1967 patients had TIMI flow data available. Propensity-score matching in the entire cohort yielded 1373 matched pairs. In the matched cohort, there was no observed difference in 30-day mortality (no-heparin 3.5% vs. heparin 3.0%, P = 0.25), MACCE (no-heparin 7% vs. heparin 6.2%, P = 0.44), and major bleeding (no-heparin 1.9% vs. heparin 1.4%, P = 0.64) between groups. Propensity-score analysis amongst those with TIMI data produced 552 matched pairs. The proportion of cases with TIMI 0 or 1 flow in the infarct-related artery (IRA) was lower among those receiving pre-hospital heparin (66% vs. 76%, P < 0.001) compared to those who did not. Conclusion : In this multicentre, propensity-score matched study, the use of pre-hospital heparin by paramedics was safe and is associated with fewer occluded IRAs in patients presenting with STEMI.